Is treatment with liraglutide efficient?
In the current context of limited economic and health resources, efficiency of drug treatments is of paramount importance, and their clinical effects and related direct costs should therefore be analyzed. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus (T2DM) which, in addition to its normoglycemic effects, induces a significant improvement in body weight and several cardiovascular risk factors. The aim of this narrative review is to summarize the available evidence about the effects of liraglutide upon cardiovascular risk factors and how these improve its cost-effectiveness profile. Despite the relatively higher cost of liraglutide as compared to other alternative therapies, liraglutide has been shown to be cost-effective when clinical indicators and total costs associated to T2DM management are analyzed.
Unidad de Endocrinología, Nutrición y Riesgo Vascular, Complejo Hospitalario Torrecárdenas, Almería, España; Servicio de Endocrinología, Clínica San Pedro, Almería, España. Electronic address: pmr.csp@gmail.com.
Pedro
P
Mezquita Raya
Servicio de Endocrinología, Clínica San Pedro, Almería, España; Unidad de Endocrinología, HGU Rafael Méndez, Murcia, España.
Rebeca
R
Reyes García
D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics* / Q000627:therapeutic use*; D000069450:Liraglutide; D012307:Risk Factors; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1
Cost-effectiveness; Coste-efectividad; Diabetes mellitus tipo 2; Liraglutida; Liraglutide; National Institute for Health and Clinical Excellence; Type 2 diabetes mellitus